Znn3bq.jpeg
±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 729  |  »Ø¸´: 7

linglingchen

Ìú³æ (СÓÐÃûÆø)


[½»Á÷] STM£º°ÐÏò×÷ÓÃÖ¬·¾¼¤ËØ»ò¿É¿ª·¢³öÖÎÁÆ2ÐÍÌÇÄò²¡µÄÐÂÐÍÁÆ·¨

12ÔÂ23ÈÕ£¬À´×Ô¹þ·ð´óѧµÄÒ»¸öÑо¿ÍŶÓͨ¹ýÑо¿ÃèÊöÁËÒ»ÖÖÁÙ´²Ç°µÄ·½·¨»ò¿É°ïÖúÖÎÁÆ2ÐÍÌÇÄò²¡¡¢Ö¬·¾¸Î¼°ÆäËü´úлÐÔ¼²²¡£¬ÎÄÕÂÖÐÑо¿Õß¿ª·¢ÁËÒ»ÖÖ¿¹Ì壬Æä¿ÉÒÔ¸ÄÉÆÍ¨¹ý°ÐÏò×÷ÓÃÖ¬·¾×éÖ¯ÖÐÃûΪaP2£¨FABP4£©µÄ¼¤ËØÀ´°ïÖú¸ÄÉÆ»úÌåµÄÆÏÌÑÌǵ÷½Ú£¬²¢ÇÒ½µµÍ·ÊÅÖСÊó¼¯ÌåµÄÖ¬·¾¸ÎÖ¢×´¡£
Development of a therapeutic monoclonal antibody that targets secreted fatty acid¨Cbinding protein aP2 to treat type 2 diabetes
http://stm.sciencemag.org/content/7/319/319ra205

Kill the messenger

A variety of metabolic messengers¡ªmany from adipose tissue itself¡ªcontrols the energy state of organs and organisms. Recently, researchers showed that the fatty acid binding protein aP2, once thought to live and work only in the cytoplasm, is also secreted by adipose tissue and spurs metabolic changes in other organs. Now, Burak and colleagues test whether secreted aP2 can serve as a therapeutic target for type 2 diabetes.

In mice, the secreted form of aP2 regulates glucose production in liver, systemic glucose homeostasis, and insulin resistance. Serum levels of aP2 were shown to be elevated in obese mice and humans and to correlate with metabolic complications. The authors identified a monoclonal antibody to aP2 that lowered fasting blood glucose, increased insulin sensitivity, and lowered both fat mass and fatty liver (steatosis) in obese mouse models, relative to a control antibody, but not in aP2-deficient mice. The antidiabetic effects of the therapeutic antibody were linked to the regulation of hepatic glucose output and peripheral glucose utilization. Together, these findings suggest that an aP2-targeted antibody that kills the messenger is a viable approach for diabetes treatment.

Abstract

The lipid chaperone aP2/FABP4 has been implicated in the pathology of many immunometabolic diseases, including diabetes in humans, but aP2 has not yet been targeted for therapeutic applications. aP2 is not only an intracellular protein but also an active adipokine that contributes to hyperglycemia by promoting hepatic gluconeogenesis and interfering with peripheral insulin action. Serum aP2 levels are markedly elevated in mouse and human obesity and strongly correlate with metabolic complications. These observations raise the possibility of a new strategy to treat metabolic disease by targeting serum aP2 with a monoclonal antibody (mAb) to aP2. We evaluated mAbs to aP2 and identified one, CA33, that lowered fasting blood glucose, improved systemic glucose metabolism, increased systemic insulin sensitivity, and reduced fat mass and liver steatosis in obese mouse models. We examined the structure of the aP2-CA33 complex and resolved the target epitope by crystallographic studies in comparison to another mAb that lacked efficacy in vivo. In hyperinsulinemic-euglycemic clamp studies, we found that the antidiabetic effect of CA33 was predominantly linked to the regulation of hepatic glucose output and peripheral glucose utilization. The antibody had no effect in aP2-deficient mice, demonstrating its target specificity. We conclude that an aP2 mAb¨Cmediated therapeutic constitutes a feasible approach for the treatment of diabetes.
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

ÐÂÒ©×ÊѶ

» ²ÂÄãϲ»¶

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

´ósusu

Ìú³æ (СÓÐÃûÆø)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÕâÖÖ°ÐÏòÒ©Îï¿ÉÒÔÖÎÁÆÌÇÄò²¡¡¢Ö¬·¾¸Î¼°ÆäËü´úлÐÔ¼²²¡£¬ºïÈüÀ×£¡
8Â¥2016-01-10 22:43:00
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
jiantu2Â¥
2015-12-29 10:32   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
liangbk3Â¥
2015-12-29 11:05   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
tzynew4Â¥
2015-12-29 12:50   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
2015-12-29 13:24   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
zhuguiqiu6Â¥
2015-12-29 13:42   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
ºÃ
2016-01-09 22:32   »Ø¸´  
1
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ linglingchen µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 315Çóµ÷¼Á +16 ÐÀϲ777 2026-04-04 17/850 2026-04-08 13:26 by lijunpoly
[¿¼ÑÐ] 325·Ö»¯Ñ§µ÷¼Á +6 15771691647 2026-04-02 6/300 2026-04-08 10:29 by screening
[¿¼ÑÐ] 347²ÄÁÏר˶Çóµ÷¼Á +15 zj8215216 2026-04-06 15/750 2026-04-08 00:22 by JourneyLucky
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +13 ºº123456 2026-04-07 14/700 2026-04-07 22:53 by À´¿´Á÷ÐÇÓê10
[¿¼ÑÐ] 302·ÖÇóµ÷¼Á Ò»Ö¾Ô¸°²»Õ´óѧ085601 +12 zyxÉϰ¶£¡ 2026-04-04 12/600 2026-04-07 02:09 by BruceLiu320
[¿¼ÑÐ] 285Çóµ÷¼Á +15 ŶßϺôo 2026-04-04 17/850 2026-04-06 23:02 by chenzhimin
[¿¼ÑÐ] ÉúÎïѧѧ˶Çóµ÷¼Á£º351·ÖÒ»Ö¾Ô¸ÄϾ©Ê¦·¶´óѧÉúÎïѧרҵ +6 ¡­¡«¡¢Íõ¡­¡« 2026-04-06 7/350 2026-04-06 18:54 by macy2011
[¿¼ÑÐ] µ÷¼Á +5 ºÃºÃ¶ÁÊé¡£ 2026-04-01 5/250 2026-04-05 17:54 by liucky
[¿¼ÑÐ] µ÷¼Á +3 ºÃºÃ¶ÁÊé¡£ 2026-04-02 3/150 2026-04-05 13:02 by arrow8852
[¿¼ÑÐ] ר˶310Çóµ÷¼Á +5 ÀÌÀÌÎÒ¡­. 2026-04-04 6/300 2026-04-04 23:33 by barlinike
[¿¼ÑÐ] 296²ÄÁÏר˶Çóµ÷¼Á +21 202451007219 2026-04-02 22/1100 2026-04-04 21:48 by hemengdong
[¿¼ÑÐ] 316Çóµ÷¼Á +9 Ä«³½_Orion926 2026-04-04 9/450 2026-04-04 21:35 by lbsjt
[¿¼ÑÐ] Ò»Ö¾Ô¸»¦985£¬326·ÖÇóµ÷¼Á +3 Áõīī 2026-04-03 3/150 2026-04-04 11:16 by ±¯É˵ÄÓóÍ·
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©¿Æ¼¼´óѧ²ÄÁϹ¤³Ì085601£¬Çóµ÷¼Á +17 cdyw 2026-04-02 18/900 2026-04-04 11:14 by w_xuqing
[¿¼ÑÐ] 311Çóµ÷¼Á +11 Ó¸ҵÄСÎâ 2026-04-02 11/550 2026-04-03 21:46 by qlm5820
[¿¼ÑÐ] 315Çóµ÷¼Á +6 ˳Àí³ÉÕÅ 2026-04-03 8/400 2026-04-03 14:04 by °ÙÁéͯ888
[¿¼ÑÐ] 320Çóµ÷¼Á +3 ũҵ¹¤³ÌÓëÐÅÏ¢¼ 2026-04-03 3/150 2026-04-03 11:40 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] 319Çóµ÷¼Á +18 Ì«ÈÝÒ×1018 2026-04-01 18/900 2026-04-03 11:18 by linyelide
[¿¼ÑÐ] һ־Ըɽ¶«´óѧ£¬085600£¬344 +7 κ×Óper 2026-04-02 8/400 2026-04-02 21:12 by °ÙÁéͯ888
[¿¼ÑÐ] 0710ÉúÎïѧÇóµ÷¼Á +9 manman511 2026-04-01 9/450 2026-04-02 10:00 by zxl830724
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û